PharmacoEconomics & Outcomes News

, Volume 800, Issue 1, pp 13–13 | Cite as

Biomarker testing in NSCLC: better survival, acceptable extra cost

Clinical study


  1. Loubiere S, et al. Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study. European Respiratory Journal 51: No. 3, Mar 2018Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations